In an in vivo study, BAY 11–7082 (a selective NF-κB inhibitor) protects rats from diabetic nephropathy through decreasing the expression of inflammatory factors such as TNF-α and IL-6 and suppressing the oxidative damage regulated by hyperglycaemia [22]. Here, IL6 is linked to diabetic kidney disease.